| [1] |
Yen EY, Shaheen M, Woo JMP, et al. 46-Year Trends in systemic lupus erythematosus mortality in the United States, 1968 to 2013: a nationwide population-based study [J]. Ann Intern Med, 2017, 167(11): 777-785.
|
| [2] |
Zucchi D, Elefante E, Schiliro D, et al. One year in review 2022: systemic lupus erythematosus [J]. Clin Exp Rheumatol, 2022, 40(1): 4-14.
|
| [3] |
Ovadya Y, Krizhanovsky V. A new twist in kidney fibrosis [J]. Nat Med, 2015, 21(9): 975-977.
|
| [4] |
LeBleu VS, Taduri G, O'Connell J, et al. Origin and function of myofibroblasts in kidney fibrosis [J]. Nat Med, 2013, 19(8): 1047-1053.
|
| [5] |
Yuan Q, Tan RJ, Liu Y. Myofibroblast in kidney fibrosis: origin, activation, and regulation [J]. Adv Exp Med Biol, 2019, 1165: 253-283.
|
| [6] |
Li L, Fu H, Liu Y. The fibrogenic niche in kidney fibrosis: components and mechanisms [J]. Nat Rev Nephrol, 2022, 18(9): 545-557.
|
| [7] |
Sheng L, Zhuang S. New insights into the role and mechanism of partial epithelial-mesenchymal transition in kidney fibrosis [J]. Front Physiol, 2020, 11: 569322.
|
| [8] |
Fu D, Senouthai S, Wang J, et al. FKN facilitates HK-2 cell EMT and tubulointerstitial lesions via the Wnt/β-catenin pathway in a murine model of lupus nephritis [J]. Front Immunol, 2019, 10: 784.
|
| [9] |
Liu Q, Du Y, Li K, et al. Anti-OSM antibody inhibits tubulointerstitial lesion in a murine model of lupus nephritis [J]. Mediators Inflamm, 2017, 2017: 3038514.
|
| [10] |
Markwald RR, Fitzharris TP, Smith WN. Sturctural analysis of endocardial cytodifferentiation [J]. Dev Biol, 1975, 42(1): 160-180.
|
| [11] |
Zeisberg EM, Potenta SE, Sugimoto H, et al. Fibroblasts in kidney fibrosis emerge via endothelial-to-mesenchymal transition [J]. J Am Soc Nephrol, 2008, 19(12): 2282-2287.
|
| [12] |
Li J, Qu X, Bertram JF. Endothelial-myofibroblast transition contributes to the early development of diabetic renal interstitial fibrosis in streptozotocin-induced diabetic mice [J]. Am J Pathol, 2009, 175(4): 1380-1388.
|
| [13] |
周颖，陈樱花，张明超，等. 系统性红斑狼疮相关血栓性微血管病血管内皮-间充质细胞转分化的研究[J]. 肾脏病与透析肾移植杂志，2017, 26(1): 20-25.
|
| [14] |
Loeffler I, Wolf G. Epithelial-to-mesenchymal transition in diabetic nephropathy: fact or fiction? [J]. Cells, 2015, 4(4): 631-652.
|
| [15] |
Sam R, Wanna L, Gudehithlu KP, et al. Glomerular epithelial cells transform to myofibroblasts: early but not late removal of TGF-beta(1) reverses transformation [J]. Transl Res, 2006, 148(3): 142-148.
|
| [16] |
Gonzalez DM, Medici D. Signaling mechanisms of the epithelial-mesenchymal transition [J]. Sci Signal, 2014, 7(344): re8.
|
| [17] |
Cruz-Solbes AS, Youker K. Epithelial to mesenchymal transition (EMT) and endothelial to mesenchymal transition (EndMT): role and implications in kidney fibrosis [J]. Results Probl Cell Differ, 2017, 60: 345-372.
|
| [18] |
Meng XM, Tang PM, Li J, et al. TGF-beta/Smad signaling in renal fibrosis [J]. Front Physiol, 2015, 6: 82.
|
| [19] |
Zhang YE. Non-Smad signaling pathways of the TGF-beta family [J]. Cold Spring Harb Perspect Biol, 2017; 9(2): a022129.
|
| [20] |
Patel S, Takagi KI, Suzuki J, et al. RhoGTPase activation is a key step in renal epithelial mesenchymal transdifferentiation [J]. J Am Soc Nephrol, 2005, 16(7): 1977-1984.
|
| [21] |
Das S, Becker BN, Hoffmann FM, et al. Complete reversal of epithelial to mesenchymal transition requires inhibition of both ZEB expression and the Rho pathway [J]. BMC Cell Biol, 2009, 10: 94.
|
| [22] |
Zavadil J, Cermak L, Soto-Nieves N, et al. Integration of TGF-beta/Smad and Jagged1/Notch signalling in epithelial-to-mesenchymal transition [J]. EMBO J, 2004, 23(5): 1155-1165.
|
| [23] |
Tan RJ, Zhou D, Zhou L, et al. Wnt/beta-catenin signaling and kidney fibrosis [J]. Kidney Int Suppl (2011), 2014, 4(1): 84-90.
|
| [24] |
Wong DWL, Yiu WH, Chan KW, et al. Activated renal tubular Wnt/β-catenin signaling triggers renal inflammation during overload proteinuria [J]. Kidney Int, 2018, 93(6): 1367-1383.
|
| [25] |
Singh SP, Tao S, Fields TA, et al. Glycogen synthase kinase-3 inhibition attenuates fibroblast activation and development of fibrosis following renal ischemia-reperfusion in mice [J]. Dis Model Mech, 2015, 8(8): 931-940.
|
| [26] |
Nyhan KC, Faherty N, Murray G, et al. Jagged/Notch signalling is required for a subset of TGF β1 responses in human kidney epithelial cells [J]. Biochim Biophys Acta, 2010, 1803(12): 1386-1395.
|
| [27] |
Burns WC, Kantharidis P, Thomas MC. The role of tubular epithelial-mesenchymal transition in progressive kidney disease [J]. Cells Tissues Organs, 2007, 185(1-3): 222-231.
|
| [28] |
Lovisa S, LeBleu VS, Tampe B, et al. Epithelial-to-mesenchymal transition induces cell cycle arrest and parenchymal damage in renal fibrosis [J]. Nat Med, 2015, 21(9): 998-1009.
|
| [29] |
Grande MT, Sanchez-Laorden B, Lopez-Blau C, et al. Snail1-induced partial epithelial-to-mesenchymal transition drives renal fibrosis in mice and can be targeted to reverse established disease [J]. Nat Med, 2015, 21(9): 989-997.
|
| [30] |
Platel V, Faure S, Corre I, et al. Endothelial-to-mesenchymal transition (EndoMT): roles in tumorigenesis, metastatic extravasation and therapy resistance [J]. J Oncol, 2019, 2019: 8361945.
|
| [31] |
Rieder F, Kessler SP, West GA, et al. Inflammation-induced endothelial-to-mesenchymal transition: a novel mechanism of intestinal fibrosis [J]. Am J Pathol, 2011, 179(5): 2660-2673.
|
| [32] |
Zhou J, Li R, Liu Q, et al. Blocking 5-LO pathway alleviates renal fibrosis by inhibiting the epithelial-mesenchymal transition [J]. Biomed Pharmacother, 2021, 138: 111470.
|
| [33] |
Yung S, Tsang RC, Sun Y, et al. Effect of human anti-DNA antibodies on proximal renal tubular epithelial cell cytokine expression: implications on tubulointerstitial inflammation in lupus nephritis [J]. J Am Soc Nephrol, 2005, 16(11): 3281-3294.
|
| [34] |
Yang J, Liu Y. Dissection of key events in tubular epithelial to myofibroblast transition and its implications in renal interstitial fibrosis [J]. Am J Pathol, 2001, 159(4): 1465-1475.
|
| [35] |
Smeets B, Kuppe C, Sicking EM, et al. Parietal epithelial cells participate in the formation of sclerotic lesions in focal segmental glomerulosclerosis [J]. J Am Soc Nephrol, 2011, 22(7): 1262-1274.
|
| [36] |
Kinloch AJ, Chang A, Ko K, et al. Vimentin is a dominant target of in situ humoral immunity in human lupus tubulointerstitial nephritis [J]. Arthritis Rheumatol, 2014, 66(12): 3359-3370.
|
| [37] |
Pieterse E, Rother N, Garsen M, et al. Neutrophil extracellular traps drive endothelial-to-mesenchymal transition [J]. Arterioscler Thromb Vasc Biol, 2017, 37(7): 1371-1379.
|
| [38] |
Zhang L, Liu L, Bai M, et al. Hypoxia-induced HE4 in tubular epithelial cells promotes extracellular matrix accumulation and renal fibrosis via NF-κB [J]. FASEB J, 2020, 34(2): 2554-2567.
|
| [39] |
Fairhurst AM, Xie C, Fu Y, et al. Type I interferons produced by resident renal cells may promote end-organ disease in autoantibody-mediated glomerulonephritis [J]. J Immunol, 2009, 183(10): 6831-6838.
|
| [40] |
Ding X, Ren Y, He X. IFN-I mediates lupus nephritis from the beginning to renal fibrosis [J]. Front Immunol, 2021, 12: 676082.
|
| [41] |
Shi S, Srivastava SP, Kanasaki M, et al. Interactions of DPP-4 and integrin β1 influences endothelial-to-mesenchymal transition [J]. Kidney Int, 2015, 88(3): 479-489.
|
| [42] |
Chen Y, Zou H, Lu H, et al. Research progress of endothelial-mesenchymal transition in diabetic kidney disease [J]. J Cell Mol Med, 2022, 26(12): 3313-3322.
|
| [43] |
Liang D, Liu S, Song Z, et al. Metformin ameliorates renal fibrosis in mice with unilateral ureteral obstruction and inhibits TGF-β1-induced upregulation of cadherin-6 in renal proximal tubule epithelial cells [J]. Diabetes, 2018, 67(Suppl 1): 2199-PUB.
|
| [44] |
Liu X, Sun N, Mo N, et al. Quercetin inhibits kidney fibrosis and the epithelial to mesenchymal transition of the renal tubular system involving suppression of the Sonic Hedgehog signaling pathway [J]. Food Funct, 2019, 10(6): 3782-3797.
|
| [45] |
Grande MT, Sánchez-Laorden B, López-Blau C, et al. Snail1-induced partial epithelial-to-mesenchymal transition drives renal fibrosis in mice and can be targeted to reverse established disease [J]. Nat Med, 2015, 21(9): 989-997.
|
| [46] |
Ruiz-Ortega M, Lamas S, Ortiz A. Antifibrotic agents for the management of CKD: a review [J]. Am J Kidney Dis, 2022, 80(2): 251-263.
|